OverviewSuggest Edit

Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. It operates through two segments: Diabetes and Obesity care and Biopharm. The Diabetes and Obesity care segment covers insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment covers the therapy areas of haemophilia, growth disorders, and hormone replacement therapy.

TypePublic
Founded1923
HQBagsværd, DK
Websitenovonordisk.com
Employee Ratings4.1
Overall CultureC+

Latest Updates

Employees (est.) (Sept 2020)44,326(+2%)
Job Openings741
Revenue (FY, 2019)KR122 B(+10%)
Share Price (Sept 2021)KR636.4
Cybersecurity ratingCMore

Key People/Management at Novo Nordisk

Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

President and Chief Executive Officer
Monique Carter

Monique Carter

Executive Vice President and Head of People & Organisation
Maziar Mike Doustdar

Maziar Mike Doustdar

Executive Vice President and Head of International Operations
Ludovic Helfgott

Ludovic Helfgott

Executive Vice President and Head of Biopharm
Karsten Munk Knudsen

Karsten Munk Knudsen

Executive Vice President and Chief Financial Officer
Doug Langa

Doug Langa

Executive Vice President and Head of North America Operations
Show more

Novo Nordisk Office Locations

Novo Nordisk has offices in Bagsværd, Hellerup, København, Køge and in 90 other locations
Bagsværd, DK (HQ)
Novo Allé 1
Hellerup, DK
Tuborg Havnevej 19
København, DK
Ørestads Blvd. 108
Køge, DK
Københavnsvej 216
Tirana, AL
EGT - Tower, Rr. "Donika Kastrioti", P. 11/1
Tizi Ouzou, DZ
Zone industrielle Aissat Idir Oued Aissi
Show all (96)

Novo Nordisk Financials and Metrics

Novo Nordisk Revenue

Embed Graph
View revenue for all periods
Novo Nordisk's revenue was reported to be kr122.02 b in FY, 2019 which is a 9.1% increase from the previous period.
DKK

Revenue (Q3, 2020)

30.9b

Gross profit (Q3, 2020)

25.8b

Gross profit margin (Q3, 2020), %

83.3%

Net income (Q3, 2020)

10.3b

EBIT (Q3, 2020)

12.8b

Market capitalization (15-Sept-2021)

1.5t

Closing stock price (15-Sept-2021)

636.4

Cash (30-Sept-2020)

25.5b

EV

1.4t
Novo Nordisk's current market capitalization is kr1.5 t.
Annual
DKKFY, 2017FY, 2018FY, 2019

Revenue

111.7b111.8b122.0b

Revenue growth, %

0%9%

Cost of goods sold

17.6b17.6b20.1b

Gross profit

94.1b94.2b101.9b
Quarterly
DKKQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

26.9b27.4b27.8b29.3b30.0b30.3b33.9b30.0b30.9b

Cost of goods sold

4.2b4.4b4.4b4.7b4.8b5.1b5.4b4.8b5.2b

Gross profit

22.7b23.1b23.3b24.6b25.2b25.2b28.5b25.2b25.8b

Gross profit Margin, %

84%84%84%84%84%83%84%84%83%
Annual
DKKFY, 2017FY, 2018FY, 2019

Cash

18.9b15.6b15.5b

Accounts Receivable

20.2b22.8b24.9b

Inventories

15.4b16.3b17.6b

Current Assets

60.1b59.1b62.5b
Quarterly
DKKQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

10.5b18.4b16.4b9.1b14.5b18.8b9.8b24.9b25.5b

Accounts Receivable

16.3b19.0b18.5b21.5b23.2b22.5b30.1b25.7b24.4b

Inventories

15.9b16.1b15.9b16.8b17.1b17.5b17.3b17.8b18.1b

Current Assets

49.9b57.5b54.1b52.7b58.7b63.4b63.2b73.6b73.7b
Annual
DKKFY, 2017FY, 2018FY, 2019

Net Income

38.1b38.6b39.0b

Depreciation and Amortization

3.2b3.9b5.7b

Inventories

(1.0b)(963.0m)(1.3b)

Accounts Payable

(401.0m)1.1b(398.0m)
Quarterly
DKKQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

10.8b21.1b30.1b10.4b20.0b30.2b11.9b22.5b32.8b

Depreciation and Amortization

732.0m1.5b2.3b1.1b2.2b4.3b1.1b2.2b4.4b

Cash From Operating Activities

9.8b25.6b37.2b9.9b24.9b41.6b10.0b34.3b51.8b

Purchases of PP&E

(2.1b)(4.5b)(6.9b)(2.6b)(4.8b)(7.0b)(1.7b)(2.9b)(4.3b)
DKKFY, 2017

Revenue/Employee

2.7m

Financial Leverage

2.1 x

P/E Ratio

3.4
Show all financial metrics

Novo Nordisk Operating Metrics

Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q4, 2019Q1, 2020Q2, 2020Q3, 2020Q4, 2020

Phase I Trials Products (Diabetes)

223224457

Phase II Trials Products (Diabetes)

22222221

Phase III Trials Products (Diabetes)

12246

Trials Products Submitted (Diabetes)

111
Show all operating metrics

Novo Nordisk Acquisitions / Subsidiaries

Company NameDateDeal Size
Emisphere TechnologiesNovember 06, 2020$1.4 b
CorvidiaJune 15, 2020$725 m
ZiyloAugust 20, 2018$800 m
CalibriumAugust 27, 2015
MB2 LLCAugust 27, 2015
Xellia PharmaceuticalsMay 21, 2013$700 m
Aldaph SpAOctober 01, 2003
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd.
Churchill Stateside Solar Fund XIV, LLC
NNE A/S
Show more

Novo Nordisk Revenue Breakdown

Embed Graph

Novo Nordisk revenue breakdown by business segment: 15.7% from Biopharmaceuticals and 84.3% from Diabetes and Obesity

Novo Nordisk revenue breakdown by geographic segment: 49.5% from North America and 50.5% from International

Human Capital Metrics

Embed Graph
Show all human capital metrics

Novo Nordisk Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Novo Nordisk Online and Social Media Presence

Embed Graph

Novo Nordisk Company Culture

  • Overall Culture

    C+

    65/100

  • CEO Rating

    B

    70/100

  • Compensation

    C+

    64/100

  • Diversity

    B

    71/100

Learn more on Comparably

Novo Nordisk News and Updates

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021

Bagsværd, Denmark, 11 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021

Bagsværd, Denmark, 10 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 August 2021

Bagsværd, Denmark, 9 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Worldwide Human Insulin Industry to 2026 - Key Players Include Biocon, Novo Nordisk and Pfizer Among Others

Dublin, July 14, 2021 (GLOBE NEWSWIRE) -- The "Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global human insulin market exhibited moderate growth during 2015-2020. Looking forw…

Prothena sells ATTR amyloidosis portfolio to Novo Nordisk for up to $1.2 billion

Shares of Prothena Corp. Plc were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a build…

Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion

Shares of Prothena Corp. Plc were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a buildu…
Show more

Novo Nordisk Frequently Asked Questions

  • When was Novo Nordisk founded?

    Novo Nordisk was founded in 1923.

  • Who are Novo Nordisk key executives?

    Novo Nordisk's key executives are Lars Fruergaard Jørgensen, Monique Carter and Maziar Mike Doustdar.

  • How many employees does Novo Nordisk have?

    Novo Nordisk has 44,326 employees.

  • What is Novo Nordisk revenue?

    Latest Novo Nordisk annual revenue is kr122 b.

  • What is Novo Nordisk revenue per employee?

    Latest Novo Nordisk revenue per employee is kr2.8 m.

  • Who are Novo Nordisk competitors?

    Competitors of Novo Nordisk include Mankind Pharma, Abbott and Amgen.

  • Where is Novo Nordisk headquarters?

    Novo Nordisk headquarters is located at Novo Allé 1, Bagsværd.

  • Where are Novo Nordisk offices?

    Novo Nordisk has offices in Bagsværd, Hellerup, København, Køge and in 90 other locations.

  • How many offices does Novo Nordisk have?

    Novo Nordisk has 96 offices.